Page last updated: 2024-09-04

vatalanib and pd 184352

vatalanib has been researched along with pd 184352 in 2 studies

Compound Research Comparison

Studies (vatalanib)	Trials (vatalanib)	Recent Studies (post-2010) (vatalanib)	Studies (pd 184352)	Trials (pd 184352)	Recent Studies (post-2010) (pd 184352)
276	42	98	185	3	74

Protein Interaction Comparison

Protein	Taxonomy	pd 184352 (IC50)
RAF proto-oncogene serine/threonine-protein kinase	Homo sapiens (human)	0.012
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	0.0263
Casein kinase II subunit alpha	Homo sapiens (human)	0.017
Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	0.0218

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP	1
Bockman, J; Rice, MC	1

Other Studies

2 other study(ies) available for vatalanib and pd 184352

Article	Year
Comprehensive analysis of kinase inhibitor selectivity. Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11 Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity	2011
Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:10 Topics: Angiogenesis Inhibitors; Benzamides; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cooperative Behavior; Diphenylamine; Drug Industry; Drugs, Investigational; Humans; Lenalidomide; Marketing; Phthalazines; Piperazines; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Stem Cell Factor; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A	2005

Article

Year

Comprehensive analysis of kinase inhibitor selectivity.

Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011

Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.

IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:10

Topics: Angiogenesis Inhibitors; Benzamides; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cooperative Behavior; Diphenylamine; Drug Industry; Drugs, Investigational; Humans; Lenalidomide; Marketing; Phthalazines; Piperazines; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Stem Cell Factor; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A

2005